ERBB2 and breast carcinoma: The ongoing OFSET phase III clinical trial will answer the question of whether the benefit of chemotherapy seen in certain subsets of pre-menopausal women with HR + HER2-negative breast cancer is due to ovarian ablative effects of chemotherapy [5].